A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

(2014) Colin D. Weekes et al.   INVESTIGATIONAL NEW DRUGS

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

(2012) Y. Xin et al.   CLINICAL CANCER RESEARCH

Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans

(2012) Yan Xin et al.   PHARMACEUTICAL RESEARCH

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

(2011) Benjamin Beck et al.   NATURE

Neuropilins: A New Target for Cancer Therapy

(2011) Camille Grandclement et al.   Cancers

Connecting Vascular and Nervous System Development: Angiogenesis and the Blood-Brain Barrier

(2010) Stephen J. Tam et al.   Annual Review of Neuroscience

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Semaphorin3a disrupts podocyte foot processes causing acute proteinuria

(2007) R. Tapia et al.   KIDNEY INTERNATIONAL